The AstraZeneca Group has long been committed to developing treatments to reduce cancer mortality worldwide. Recently, the company announced that it will introduce new advances in the disease in the coming days.
The AstraZeneca group will, according to the latest news, present its new developments concerning cancer. This presentation will be made during the 2020 Virtual Congress of the European Society of Medical Ontology (ESMO), to be held from 19 to 21 September.
AstraZeneca also points out that their drugs and pipeline molecules have already been mentioned in 114 ESMO summaries. This is a healthy record for the group as it featured in 20 oral presentations and two presidential symposia among the 144 abstracts. These data show the potential of the company in early-stage cancer treatment and pipeline.
Following the announcement of the future presentation of AstraZeneca's cancer developments, José Baselga, who is recognised as Executive Vice President and R&D in Oncology, made a statement. In his statement, he emphasized that the final overall survival data collected by PROfound reveal the efficacy of drugs designed against biomarkers (for prostate cancer).
The Executive Vice President also mentioned that the ADAURA and PACIFIC data are proof of rigour in the workplace. These data demonstrate society's commitment to the early detection, interception and treatment of cancer. These steps are given special attention in order to achieve the desired result.
AstraZeneca has been involved in the fight against cancer for several years. The projects it develops are generally devoted to finding cures to relieve cancer patients. A few months ago, the British pharmaceutical group signed a partnership with Daiichi Sankyo. This partnership consists of a $6 billion investment by AstraZeneca in Daiichi Sankyo.
This will enable the pharmaceutical company to develop and market the anti-cancer drug developed by the Daiichi Sankyo Group of Japan. As a reminder, the two companies had already had to conclude a similar licensing agreement last year, in 2019, for $6.9 billion. Their recent partnership also includes a product in clinical trials. It's called DS-1062, a product that will treat lung cancer.
However, DS-1062 cannot treat small cells as well as breast cancer called " triple négatif " which is particularly aggressive. In this partnership, the two groups share equally in the research and development and other commercial costs related to the product. The same applies to profits from worldwide sales, except for the Japanese market, for which Daiichi Sankyo will have to retain its rights exclusively.